e-Therapeutics (United Kingdom)

Recent papers from e-Therapeutics (United Kingdom)

1. Electrophysiological Improvements in Patients with Dravet Syndrome Following Treatment with Zorevunersen, an Investigational Antisense Oligonucleotide (S19.001)Neurology · 2026
2. Zorevunersen Demonstrates Potential as a Disease-modifying Therapy in Patients with Dravet Syndrome Through Durable Seizure Reduction and Improvements in Cognition, Behavior, and Quality of Life Through 36 Months of Treatment in Open-label Extension Studies (S19.007)Neurology · 2026
3. First-in-human study of cavitation-enhanced drug delivery (CEeDD) by sonosensitive particles and focused ultrasound applied to colorectal metastases in the liver.Journal of Clinical Oncology · 2026
4. Autologous macrophage therapy increases transplant-free survival in cirrhosis: Long-term follow-up of a phase 2 clinical trialCell stem cell · 2026
5. Abstract 1712: PA289: A first-in-class prodrug payload with a novel mechanism of action and favorable efficacy/safety profileCancer Research · 2026
6. Abstract 1609: Unlocking pMHC target space for next generation T cell engagers in oncology and autoimmunityCancer Research · 2026
7. OTHR-02. An international accelerator programme for novel brain tumour therapies: Early impact and lessons learnedNeuro-Oncology Pediatrics · 2025
8. Spontaneous clinical and anatomical pathology findings in SDRG rats.2026
9. Correction: Grant et al. Low pH, High Stakes: A Narrative Review Exploring the Acid-Sensing GPR65 Pathway as a Novel Approach in Renal Cell Carcinoma. Cancers 2025, 17, 3883Cancers · 2026
10. Neural Hearing Loss: Mechanisms, Diagnosis and Treatment HorizonsJournal of the Association for Research in Otolaryngology · 2026
11. An open‐label, single‐arm, dose‐escalating concentration–QT study to investigate the cardiac effects and safety of paroxetine in healthy adultsBritish Journal of Clinical Pharmacology · 2026
12. Early analysis of activity in esophageal cancer during phase 1 dose escalation of IKS014, a HER2-targeting antibody drug conjugate (ADC), in participants with advanced HER2+ and HER2 low solid tumors.Journal of Clinical Oncology · 2026
13. MLLT1/3 targeted protein degradation as the best-in-class approach for targeting the super elongation complex (SEC) in acute leukemia, including menin inhibitor refractory diseaseBlood · 2025
14. A first-in-class oral clinical candidate targeting MLLT1 and 3 degradation for the treatment of advanced AML and ALL including menin inhibitor resistant / refractory diseaseBlood · 2025
15. Morphological dormancy, embryo growth and pericarp restraint during crop and wild Apiaceae mericarp germination in response to ambient temperaturePlanta · 2025
16. Structural basis for chemotype diversity in small molecule GLP-1 receptor agonist drug discovery2025
17. Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers2025
18. An International Novel Therapeutics Accelerator for Brain Tumours: Early Impact and Lessons LearnedNeuro-Oncology · 2025
19. Glycosylated extracellular matrix drives immune suppression by controlling T cell movement, macrophage phenotype, and macrophage-T cell crosstalk in triple negative breast cancer2025
20. Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patientsBlood · 2025